g****e
发帖数: 1426 | 1 Bought cytr/lxrx last week, cytr p2 results on indication NSCLC will be
release in next June. Lxrx for partnership news this month or early next
year.
Still hold Isis, looking for EU approval this month.
Watch arql, it has solid cash over 120m at hand. The partner suspended/
failed on tivantinib trials on NSCLC indication caused the big drop. But
insider buying and other indication trials on hcc and Crc could drive sp up
big, especially crc p2 results due at the end of this year or early next
year. Your thoughts on arql? |
g****e
发帖数: 1426 | 2 Nsclc stands for non-small cell lung cancer, the potential market is huge.
Onty is also in my watch list, Stimuvax p3 result due early next year too. |
a********n
发帖数: 134 | 3 I just bought some HZNP, which seems have good potential. |
k**********4
发帖数: 16092 | 4 r u a professional ? do u know how competitive the oncology
drug market is? it is very tough ,
just want to remind you of the potential risks.
【在 g****e 的大作中提到】
: Nsclc stands for non-small cell lung cancer, the potential market is huge.
: Onty is also in my watch list, Stimuvax p3 result due early next year too.
|
g****e
发帖数: 1426 | 5 I don't have them anymore. Hznp will have eu approval too this month.
Sppi belinostat data will be this month. Amrn NCE/Bo ... So many exciting,
going to be a very volatility period for these biotech stocks. Trading them
accordingly. Good luck!! |
g****e
发帖数: 1426 | 6 Thanks for the reminder, dndn is a good example.
【在 k**********4 的大作中提到】
: r u a professional ? do u know how competitive the oncology
: drug market is? it is very tough ,
: just want to remind you of the potential risks.
|
S*P
发帖数: 7575 | 7 DNDN的产品是自己的，ONTY是代理
投机还是可以的 |
J*********B
发帖数: 822 | 8 Niu!
up
【在 g****e 的大作中提到】
: Bought cytr/lxrx last week, cytr p2 results on indication NSCLC will be
: release in next June. Lxrx for partnership news this month or early next
: year.
: Still hold Isis, looking for EU approval this month.
: Watch arql, it has solid cash over 120m at hand. The partner suspended/
: failed on tivantinib trials on NSCLC indication caused the big drop. But
: insider buying and other indication trials on hcc and Crc could drive sp up
: big, especially crc p2 results due at the end of this year or early next
: year. Your thoughts on arql?
|
g****e
发帖数: 1426 | 9 Watch for these 3 oncology stocks:
ONTY, CYTR and ARQL
all have very decent insider buying recently. Good mid term (6 months)
investment no matter how the global market does.
Sold my LXRX and MSFT positions today and invested half of my power in these
3 stocks. Look for good return soon. |
